کارگاه‌های آموزشی مرکز اطلاعات علمی

آموزش مهارت‌های کاربردی ISI در تدوین و چاپ مقالات

روش تحقیق گمی

آموزش نرم‌افزار برای پژوهشگران

Word
Comprehensive competitive endogenous RNA network analysis reveals EZH2-related axes and prognostic biomarkers in hepatocellular carcinoma

Mohammad Hossein Donyavi 1, Sadra Salehi-Mazandarani 2, Parvaneh Nikpour 2, 3*

1 Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
2 Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan, Iran

Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for approximately 80% of cases and ranking fourth cause of cancer-related deaths worldwide (1-3). HCC has a poor prognosis because it is usually detected at the advanced stages. There are only a few therapeutic options with limited health benefits for the treatment of HCC (4, 5). Therefore, new prognostic and diagnostic biomarkers and novel therapeutic targets are required.

Different types of RNAs have been shown to compete for binding to the same microRNAs (miRNAs) through their miRNA response elements (MREs). These interactions and competitions among RNAs referred to as competing endogenous RNAs (ceRNAs) result in the formation of ceRNA networks (6). The investigation of these networks will contribute to a better understanding of the molecular mechanisms underlying cancer progression as well as the development of new biomarkers and therapeutic targets.

ceRNA networks are important for HCC progression (7). The roles of IncRNAs and circRNAs as ceRNAs in miRNA-mediated gene expression modulation in HCC have been demonstrated over the last decade (8, 9). Xiong Dd et al. established a circRNA-miRNA-mRNA ceRNA network in HCC and identified 7 hub genes involving in cancer-related pathways and biological functions (10). Luo Y et al. constructed a lncRNA-miRNA-mRNA ceRNA network in HCC and identified four genes associating with survival (CCNA2, CHEK1, FOXM1 and MCM2) (11). Another study established a ceRNA network in HCC and identified 9 IncRNAs as hub genes enriched in various cancer-related processes (12).

Although there are several studies demonstrating the vital interactions and functions of ceRNAs in HCC, little is known about the four-component ceRNA network in which lncRNAs, circRNAs, and miRNAs compete for binding to the same miRNAs. These highly informative networks, which include four distinct types of ceRNAs, can provide a more comprehensive picture of the regulatory interactions occurring in cancer.

Using the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases, we identified differentially expressed lncRNAs, miRNAs, mRNAs, and circRNAs in cancerous versus paracancerous HCC tissues (13, 14). Their interactions were then analyzed, and a ceRNA network comprised of all four types of mentioned RNAs

*Corresponding author: Parvaneh Nikpour. Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical sciences, Isfahan, Iran, Tel: +98-31-37929143; Fax: +98-31-36688597; Email: pnikpour@med.mui.ac.ir
was constructed. We used mRNAs of the ceRNA network to identify Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and to construct a Protein-Protein Interaction (PPI) network. Furthermore, survival analysis was performed to identify ceRNAs which may serve as prognostic biomarkers in HCC. The pipeline of the current study is depicted in Figure 1.

Materials and Methods

RNA sequencing data

A total of 422 HCC miRNA-seq data samples (372 cancerous and 50 paracancerous) and 421 HCC RNA-seq data samples (371 cancerous and 50 paracancerous) were retrieved from the TCGA database using the TCGAbiolinks package in the RStudio software (15). Then, samples from patients with both RNA-seq and miRNA-seq data (367 cancerous and 50 paracancerous data samples for each RNA-seq and miRNA-seq data) were selected for further analysis.

Batch effect examination and correction

The batch effect is a complication that researchers face when analyzing high-throughput data with technical differences and results from non-biological conditions that affect the results of studies (16, 17). The swamp package in the RStudio software was used to identify strong batch effects in RNA-seq data (containing Tissue Source Site (TSS), portion, and plate) and miRNA-seq data (containing TSS, portion, and plate). Then, batch effect correction was performed on both RNA-seq and miRNA-seq data by using ComBat_seq from the sva package (18).

Microarray data

The raw gene expression profiles of circRNAs in HCC were retrieved from the GEO database (https://www.ncbi.nlm.nih.gov/geo/) consisting of GSE94508 (including 5 cancerous and 5 paracancerous samples) and GSE97332 (including 7 cancerous and 7 paracancerous samples). The two datasets were combined, and the batch effect was removed through the sva package (19).

Identification of differentially expressed RNAs (DERs)

We compared 367 cancerous and 49 paracancerous RNA-seq and miRNA-seq data samples in order to identify differentially expressed mRNAs (DEMs), lncRNAs (DELs), and miRNAs (DEMis), using the DESeq2 package, with the threshold of \(|\log_2 FC| > 2\) and adjusted \(P\)-value < 0.01 (20). To investigate differentially expressed circRNAs (DECs) in 12 cancerous and 12 paracancerous samples, the limma R package was utilized with the threshold of \(|\log_2 FC| > 1.5\) and adjusted \(P\)-value < 0.05 (21). The ggplot2 and pheatmap packages were utilized to generate volcano and heatmap plots of DERs in the RStudio software.

Interaction prediction and construction of a ceRNA network

We annotated RNA-seq data using the biomaRt R package based on the Ensembl genome browser (22). We utilized the multiMiR R package to retrieve interactions between DEMs, DEMls, and DEMis, using the DEseq2 package, with the threshold of \(|\log_2 FC| > 2\) and adjusted \(P\)-value < 0.01 (20). To investigate differentially expressed circRNAs (DECs) in 12 cancerous and 12 paracancerous samples, we used the CircInteractome online database with a score > 0.5 (27). We used the CircInteractome online database to identify DECs and DEMIs interactions with context+ score percentile ≥ 90 (28). The ceRNA network was constructed using Cytoscape software (version 3.8.1) (29). A sub-network was established by using “cytoHubba” (a plugin in Cytoscape software) for identification of hub genes in the network based on their topological feature (degree) (30).

Functional enrichment analysis

The KOBAS 3.0 online web tool was used to identify GO and KEGG pathways relating to the ceRNA network’s DEMs (31). The corrected \(P\)-value < 0.001 was considered as a significant cut-off for GO analysis. Moreover, the corrected \(P\)-value<0.01 was considered as a significant cutoff for KEGG analysis. The ggplot2 R package and Cytoscape software were used to visualize KEGG pathways.
and the genes associated with them. Furthermore, the GOplot R package was utilized to visualize the results of the GO analysis (32).

**Establishment of a PPI Network and a sub-network**

We established a PPI network based on the ceRNA network's DEMs, using the online STRING database (33). Subsequently, in Cytoscape, free nodes were eliminated, and hub genes were detected via cytoHubba. The first hub gene (according to the degree feature) was selected to construct a sub-network based on its interactions from the ceRNA network.

**Survival analysis**

Survival analysis was performed on the ceRNA sub-network’s DEMs, DEMis, and DELs to explore potential HCC prognostic biomarkers. The survival R package was utilized for survival analysis. Cancerous samples were divided into low and high expression groups based on the mean expression of each RNA, and the Kaplan-Meier method was employed to perform the analysis. P-value < 0.05 and Hazard Ratio (HR) ≠ 1 were considered as statistically significant thresholds. The clinical information of the patients were extracted from the TCGA database using the TCGAbioLinks R package. The survminer package was utilized for drawing survival plots. Box plots were also generated using ggpubr R package.

**Statistical analyses**

Spearman correlation among miRNA-seq and RNA-seq samples were performed separately using the TCGAbioLinks R package based on correlation > 0.7. The survivalROC package was utilized to examine prognostic values using the receiver operation curve (ROC) plot (34).

**Results**

**Batch effects examination and correction in TCGA data**

There were 367 cancerous and 50 paracancerous miRNA-seq and RNA-seq data samples from the same HCC patients. The swamp R package was used to generate prince plots to investigate batch effects in RNA-seq and miRNA-seq data. Both miRNA-seq and RNA-seq data have been shown to exhibit significant batch effects based on their plate ID (Supplementary Figure 1a and b). Due to the statistical limitations of ComBat_seq, data from a paracancerous sample with a unique batch ID were omitted from miRNA-seq and RNA-seq data. Finally, 367 cancerous and 49 paracancerous data samples remained for RNA-seq and miRNA-seq data samples from the same HCC patients.

**Supplementary Figure 1.** Batch effects examination in RNA-seq and miRNA-seq data. a) Prince plot of RNA-seq data before batch effect correction, b) Prince plot of miRNA-seq data before batch effect correction, c) Prince plot of RNA-seq data after batch effect correction, d) Prince plot of miRNA-seq data after batch effect correction
miRNA-seq data analyses, respectively. The batch effect was then corrected according to plate ID in both RNA-seq and miRNA-seq data (Supplementary Figure 1c and d).

**Differentially expressed RNAs in HCC**

Based on the threshold of $|\log_{2}(FC)| > 2$ and adjusted $P$-value $< 0.01$, 755 DELs (608 upregulated and 147 downregulated), 1509 DEMs (1089 upregulated and 420 downregulated) and 113 DEMis (109 upregulated and 4 downregulated) were identified in HCC. Additionally, 45 DECs (29 upregulated and 16 downregulated circRNAs) were identified based on the threshold of $|\log_{2}(FC)| > 1.5$ and adjusted $P$-value $< 0.05$ in cancerous compared to paracancerous HCC samples. The volcano and heatmap plots depict DERs and the distribution of their expression in cancerous and paracancerous HCC samples (Figure 2 and 3).

**Interaction prediction and constructing a ceRNA network**

Utilizing the TargetScan, miRTarBase, and miRDB databases via the multiMiR R package, 1078 interactions existing at least in one of the three mentioned databases were identified between DEMs and DEMis containing 95 unique DEMis. Among the 95 DEMis interacting with DEMs, CircInteractome and RNAInter databases revealed 24 DECs-DEMIs and 8 DELs-DEMIs interactions, respectively. Collectively, 297 interactions were identified and used to construct a ceRNA network. Then, a four-component ceRNA network was constructed with 239 nodes and 295 edges (one axis which had no connection to the other parts of the network was deleted (ASB15/ hsa-miR-1251-5p/ hsa_circ_0072088).

The four-component ceRNA network included 8 lncRNAs (8 upregulated), 23 circRNAs (16 upregulated and 7 downregulated), 18 miRNAs (18 upregulated), and 190 mRNAs (133 upregulated and 57 downregulated) (Figure 4a). According to the network's topological feature (degree), hsa-miR-182-5p had the highest degree (degree = 41) and was selected for extracting its sub-network from the ceRNA network (Figure 4b). Moreover, hsa_circ_0007456 was a hub gene in the ceRNA network (it was the first hub gene based on the degree feature (degree = 6) of all nodes except miRNAs). Interestingly, hsa-miR-182-5p interacted with hsa_circ_0007456 in the ceRNA network.

**Figure 4.** ceRNA network and a sub-network in HCC. a) ceRNA network including DELs (orange), DECs (green), DEMs (blue) and DEMis (purple). b) A sub-network was extracted from the ceRNA network. hsa-miR-182-5p has the highest degree in the ceRNA network. Triangle and rectangle shapes represent upregulated and downregulated RNAs, respectively.

**Figure 5.** Significant KEGG pathways relating to the DEMs of the ceRNA network. a) A dot plot showing significant KEGG pathways. The Y axis represent the name of each signaling pathway and X axis represent $-\log_{10}$ (adjusted $P$-value) of each pathway. The size of the dots indicates the number of genes involved in the related signaling pathway. The significance level of the pathways is shown by changes in the color scale. b) A network including signaling pathways and the genes relating to them. Pink and blue circles represent pathways and genes, respectively.
Functional enrichment analysis

KEGG pathway analysis showed significant pathways such as calcium signaling pathway, protein digestion and absorption, hepatitis B, microRNAs in cancer, gap junction, pathways in cancer, and cellular senescence with corrected P-value < 0.01 (Figure 5). On the other hand, GO enrichment analysis revealed 30 terms with corrected P-value < 0.001 (Figure 6). Among these GO terms, biological process (BP), cellular component (CC), and molecular function (MF) were associated with 11, 11, and 8 terms, respectively. The supplementary files contain all significant KEGG pathways (corrected P-value < 0.01) and GO terms (corrected P-value < 0.001) (Supplementary file 1 and 2).

Protein-protein interaction (PPI) and screening of hub genes

The ceRNA network-related mRNAs were utilized for constructing a PPI network. A PPI network with 118 nodes and 301 edges was generated using the STRING online database (Figure 7a). There were 10 hub genes in the network with degree greater than 15, which the enhancer of zeste homolog 2 (EZH2) had the highest degree (Figure 7b). EZH2 plays a critical role in HCC (35, 36). As a result, we investigated its ceRNA network axes and introduced both lncRNAs and circRNAs as competitors for EZH2. EZH2 was
Table 1. Survival-related ceRNAs from the sub-network of EZH2. The columns of group and patients represent the number of patients with high and low expression of each RNAs. †: hazard ratio

| Type | Name          | Group | Patients | P-value | HR† |
|------|---------------|-------|----------|---------|-----|
| mRNA | EZH2          | High  | 185      | 3.0036  | 1.9 |
|      |               | Low   | 181      |         |     |
|      | ANLN          | High  | 187      | 3.0083  | 1.82|
|      |               | Low   | 179      |         |     |
|      | MYEF2         | High  | 174      | 0.0112  | 1.78|
|      |               | Low   | 192      |         |     |
|      | T8X4          | High  | 138      | 0.0117  | 1.74|
|      |               | Low   | 236      |         |     |
| miRNA | MCOLN3       | High  | 149      | 0.0023  | 1.71|
|       |               | Low   | 217      |         |     |
|       | ROBO1         | High  | 214      | 0.0063  | 1.66|
|       |               | Low   | 152      |         |     |
|       | RAGGAP1       | High  | 191      | 0.0075  | 1.62|
|       |               | Low   | 175      |         |     |
|       | KCN6          | High  | 144      | 0.028   | 1.48|
|       |               | Low   | 222      |         |     |
|       | DDX53         | High  | 124      | 0.038   | 1.47|
|       |               | Low   | 242      |         |     |
|       | GPM5A         | High  | 187      | 0.015   | 1.65|
|       |               | Low   | 179      |         |     |
|       | CDKN2B-AS1    | High  | 198      | 0.005   | 1.67|
|       |               | Low   | 168      |         |     |
| lncRNA | HAGLR        | High  | 177      | 0.017   | 1.54|
|       |               | Low   | 189      |         |     |
| miRNA | hsa-miR-217-5p| High  | 186      | 0.016   | 1.55|
|       |               | Low   | 179      |         |     |

found to be associated with 7 axes which correlated with circRNAs or lncRNAs (hsa_circ_0040705-hsa-miR-527-EZH2 / hsa_circ_0040705-hsa-miR-518a-5p–EZH2 / hsa_circ_0069104-hsa-miR-527-EZH2 / hsa_circ_0069104-hsa-miR-518a-5p–EZH2 / HAGLR-hsa-miR-217-5p–EZH2 / CRNDE-hsa-miR-217-5p–EZH2/CDKN2B-AS1–hsa-miR-

Figure 8. Survival-related and box plots of the three survival-related ceRNAs. a) Survival plot of EZH2, b) Survival plot of ANLN, c) Survival plot of MYEF2. Purple and pink colors represent low and high gene expression in samples. Y and X axes represent survival percentage of patients and time, respectively. d) Receiver Operating Characteristic (ROC) curve plot of EZH2, e) ROC curve plot of ANLN, f) ROC curve plot of MYEF2. Red, blue and green colors represent one, three and five-year survival area under the ROC curve (AUC), respectively. g) Boxplot of EZH2, h) Boxplot of ANLN, i) Boxplot of MYEF2. Purple and pink colors represent paracancerous and cancerous HCC samples, respectively.
217-5p–EZH2) Subsequently, the EZH2 sub-network was established (Figure 7c).

**Survival-related RNAs**

Univariate survival analysis was conducted to identify survival-related RNAs from the sub-network of EZH2. A total of 13 RNAs (10 mRNAs, 2 IncRNAs, and 1 miRNA) were revealed as survival-associated RNAs in HCC based on *P*-value<0.05 and HR≠1 (Table 1). Among these DERs, EZH2, ANLN, and MYEF2 had the highest HR and HCC patients who expressed higher levels of these RNAs had poorer survival rate (Figure 8a-f). Roc curve plots indicated that these three RNAs could be effective prognostic biomarkers in HCC patients (Figure 8d-f). The expression changes of these three RNAs between cancerous and paracancerous samples have also been shown (Figure 8g-i).

**Discussion**

HCC is the fourth cause of cancer-related death in the world (1). While numerous studies have been conducted to elucidate the molecular mechanisms underlying the progression of HCC, they have not been completely understood. IncRNAs and circRNAs are two types of ceRNAs which their competition affects the development of cancers, including HCC (8, 9). Identification of these interactions will aid in our understanding of the molecular mechanisms underlying HCC and the development of novel diagnostic and prognostic biomarkers.

The current study investigated the interactions among four types of RNAs in HCC, including IncRNAs, circRNAs, mRNAs, and miRNAs and their four-component ceRNA network. After correcting batch effects, we identified 755 DELs, 1509 DEMs, 113 DEMis, and 45 DECs between cancerous and paracancerous HCC samples. A ceRNA network with 239 nodes and 295 edges was constructed based on the predicted interactions of DERs. Enrichment analysis was then performed based on the mRNAs from the network and revealed significant signaling pathways and GO terms. These results can help us to better understand molecular and cellular processes involving in the development of HCC. The mRNAs from the ceRNA network were then utilized to establish a PPI network. EZH2 had the highest degree among the hub genes in the PPI network.

Examining ceRNAs from the ceRNA network revealed hsa-miR-182-5p as the highest degree hub gene and hsa_circ_0007456 as a hub gene based on degree of all nodes except miRNAs. The two hub genes directly interact with each other in the ceRNA network, and their sub-network was extracted. miR-182-5p induces proliferation of HCC cells through AKT/FOXO3a signaling pathway, and its increased expression is associated with poor prognosis in HCC patients (37). Downregulation of hsa_circ_0007456 in HCC tissues has been reported and it can affect natural killer cell-mediated cytotoxicity through the hsa_circ_0007456/miR-6852-3p/ICAM-1 axis in HCC (38).

EZH2, a critical transcription regulator, is a subunit of the polycomb repressive complex 2 (PRC2), which can influence the expression of its target genes in various ways, such as methylation of Lys-27 in histone 3 (39, 40). Overexpression of EZH2 has been identified in various cancers, including gastric cancer, thyroid carcinoma, prostate cancer, and HCC (36, 41-43).

EZH2 overexpression is associated with HCC progression and metastasis (35). EZH2 can induce tumorigenesis by affecting tumor-suppressive genes and initiating cancer-related molecular processes like miRNA silencing, non-canonical transcription regulation, and NF-kB activation (44). Therefore, new strategies for manipulation of EZH2 may be developed to improve cancer therapy in the near future (44).

Different studies have identified the role of EZH2 as an epigenetic modifier in HCC. In a study conducted by Au SL et al. it was revealed that EZH2 can epigenetically inhibit the expression of tumor-suppressor miRNAs, such as miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b in HCC (35). Another study demonstrated that the expression of immune checkpoint inhibitor, programmed death-ligand 1 (PD-L1), can be suppressed by EZH2 in HCC through methylation of its encoding gene and IRF1 which is an essential transcription factor for the expression of PD-L1 (45). Xu L et al. revealed that ectopic overexpression of miR-101 as a tumor suppressor inhibits the progression, invasion, and proliferation of HCC by directly targeting and decreasing the expression of EZH2 (46). A study published in 2019 constructed a ceRNA network in HCC and demonstrated the interaction of EZH2 and its competitors with hsa-miR-217. Some of its competitors are also identified in this study such as DACH1 and CRNDE (47).

In the EZH2 related sub-network, three miRNAs (hsa-miR-527, hsa-miR-518a-5p, and hsa-miR-217-5p) interacted with EZH2. It has been reported that miR-527 may be involved in the progression of HCC by targeting Glypican-3 (48). Contribution of miR-217 in tumor progression of several cancer types including hepatocellular carcinoma has been documented (49).

In the present study, we demonstrated that overexpression of EZH2 was negatively associated with overall survival in HCC patients, with the highest hazard ratio of all survival-related RNAs. Previous studies have established that overexpression of EZH2 is associated with a poor prognosis in various types of cancer (50). Notably, it has been reported that overexpression of EZH2 is associated with tumor progression, aggressiveness, and poor prognosis in HCC (45, 51-54). A recent study conducted by Zhang et al. revealed that EZH2 is overexpressed in HCC and correlates with poor survival. They indicated that silencing EZH2 inhibits the viability, migration, and invasion of HCC cells via the TGF-β–MTA1–SMAD7–SMAD3–SOX4–EZH2 signaling cascade (52). Additionally, Guo et al. reported that high EZH2 expression is associated with poor overall survival, disease-specific survival, progression-free survival, and relapse-free survival in nearly all patients with HCC. Furthermore, they discovered a relationship between EZH2 and major MHC class I antigen presentation molecules, indicating that it plays an immunosuppressive role (53). In another study, Xu et al. revealed that increased EZH2 expression is associated with increased tumor size, metastasis, relapse, and an unfavorable prognosis in HCC (54). Collectively, these findings suggest that EZH2 may be a useful prognostic biomarker in patients with HCC.

**Conclusion**

Our study identifies a novel four-component ceRNA network consisting of four types of RNAs in HCC and reveals EZH2-related ceRNA axes. Future studies will elucidate the precise roles of these axes in the pathogenesis of HCC.
Three miRNAs (hsa-miR-527, hsa-miR-518a-5p, and hsa-miR-217-5p) interacting with EZH2, may be used to inhibit EZH2’s oncogenic function in the future. Furthermore, we identified ceRNAs associated with survival in the sub-network of EZH2, which may be helpful in survival-related research aimed at identifying prognostic biomarkers in HCC. Further studies are needed to examine and validate these conclusions experimentally.

Acknowledgment

This original article was supported in part by a research grant from Isfahan University of Medical Sciences, Isfahan, Iran.

Ethical Approval

Approval was obtained from the ethics committee of Isfahan University of Medical Sciences, Isfahan, Iran. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Authors’ Contributions

PN Designed the study; MHD and SSM Collected data and performed analyses; PN, SSM and MHD Discussed the results and strategy; PN Supervised, directed and managed the study; MHD, SSM and PN Drafted the manuscript and approved the final version to be published.

Conflicts of Interest

The authors report no conflict of interest.

References

1. Ferrante ND, Pillai A, Singal AG. Update on the diagnosis and treatment of hepatocellular carcinoma. Gastroenterol Hepatol 2020; 16:506-516.
2. Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res 2020; 9:1-10.
3. Yang JD, Hainaut P, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16:589-604.
4. Akqhanti A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Medicina (Kaunas) 2019; 55:526-547.
5. Ogunwobi OO, Haricharran T, Huaeman J, Galuza A, Odumuwagun O, Tan Y, et al. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25:2279-2293.
6. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011; 146:353-358.
7. Wang Y, Hou J, He D, Sun M, Zhang P, Yu Y, et al. The emerging function and mechanism of ceRNAs in cancer. Trends Genet 2016; 32:211-224.
8. Fu L, Jiang Z, Li T, Hu Y, Guo J. Circular RNAs in hepatocellular carcinoma: functions and implications. Cancer Med 2018; 7:3101-3109.
9. Mai H, Zhou B, Liu Y, Yang F, Conran C, Ji Y, et al. Molecular pattern of IncRNAs in hepatocellular carcinoma. J Exp Clin Cancer Res 2019; 38:198-212.
10. Xiong Dd, Dang Yw, Lin P, Wen Dy, He Rq, Luo Dz, et al. A circRNA–miRNA–mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma. J Transl Med 2018; 16:220-240.
11. Luo Y, Li H, Huang H, Xue L, Li H, Liu L, et al. Integrated analysis of ceRNA network in hepatocellular carcinoma using bioinformatics analysis. Medicine (Baltimore) 2021; 100:1-10.
12. Yan Y, Yu J, Liu H, Guo S, Zhang Y, Ye Y, et al. Construction of a long non-coding RNA-associated ceRNA network reveals potential prognostic IncRNA biomarkers in hepatocellular carcinoma. Pathol Res Pract 2018; 214:2031-2038.
13. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207-210.
14. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Oznerger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013; 45:1113-1120.
15. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an r/biocoregulator package for integrative analysis of TCGA data. Nucleic Acids Res 2016; 44:71-81.
16. Lauss M, Visne I, Krieger A, Ringnér M, Jönsson G, Höglund M. Monitoring of technical variation in quantitative high-throughput datasets. Cancer Inform 2013; 12:193-201.
17. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010; 11:733-739.
18. Zhang Y, Parmigiani G, Johnson WE. ComBat–seq: batch effect adjustment for RNA-seq count data. NAR Genom Bioinform 2020; 2:1-10.
19. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012: 28:882-883.
20. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15:550-564.
21. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43:47-59.
22. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the r/bioccoregulator package biomart. Nat Protoc 2009; 4:1184-1191.
23. Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multmiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res 2014; 42:133-142.
24. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015; 4:1-38.
25. Wong N, Wang X. MiRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 2015; 43:146-152.
26. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. MiRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 2018; 46:296-302.
27. Lin Y, Liu T, Cui T, Wang Z, Zhang Y, Tan P, et al. RNAInter in 2020: RNA interactome repository with increased coverage and annotation. Nucleic Acids Res 2019; 48:189-197.
28. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol 2016; 13:34-42.
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13:2498-2504.
30. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 2014; 8:11-17.
31. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res 2011; 39:316-322.
32. Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visualizing biological pathway data. Bioinformatics 2005; 21:3339-3340.
33. Kozomara A, Goryukova E. UniProtKB/Swiss-Prot: the human protein sequence database at the dawn of the post-genome era. Nucleic Acids Res 2016; 44:D530-535.
for visually combining expression data with functional analysis. Bioinformatics 2015; 31:2912-2914.
33. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pryysalo S, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/ measurement sets. Nucleic Acids Res 2020; 49:605-612.
34. Haegerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56:337-344.
35. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012; 56:622-631.
36. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92:1754-1758.
37. Cao MQ, You AB, Zhu XD, Zhang W, Zhang YY, Zhang SZ, et al. MiR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol 2018; 11:12-33.
38. Shi M, Li ZY, Zhang LM, Wu XY, Xiang SH, Wang YG, et al. Hsa_circ_0007456 regulates the natural killer cell-mediated cytotoxicity toward hepatocellular carcinoma via the miR-6852-3p/ICAM-1 axis. Cell Death Dis 2021; 12:94:106.
39. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol 2020; 13:104-115.
40. Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med 2016; 22:128-134.
41. Gan L, Xu M, Hua R, Tan C, Zhang J, Gong Y, et al. The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. J Hematol Oncol 2018; 11:9-20.
42. Pellecchia S, Sepe R, Decaussin-Petrucci M, Ivan C, Shimizu M, Coppola C, et al. The long non-coding RNA prader willi/angelman region RNA5 (PAR5) is downregulated in anaplastic thyroid carcinomas where it acts as a tumor suppressor by reducing EZH2 activity. Cancers 2020; 12:235-252.
43. Varambally S, Dhanasukar SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-629.
44. Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol 2017; 29:375-381.
45. Xiao G, Jin LL, Liu CQ, Wang YC, Meng YM, Zhou ZG, et al. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. J Immunother Cancer 2019; 7:300-314.
46. Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, et al. MicroRNA-191 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014; 60:590-598.
47. Liao X, Wang X, Huang K, Han C, Deng J, Yu T, et al. Integrated analysis of competing endogenous RNA network revealing potential prognostic biomarkers of hepatocellular carcinoma. J Cancer 2019; 10:3267-3283.
48. Nomura K, Kitanka A, Iwama H, Tani J, Nomura T, Nakahara M, et al. Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. Oncol Lett 2021; 21:229-236.
49. Zhou S, Zhu C, Pang Q, Liu HC. MicroRNA-217: A regulator of human cancer. Biomed Pharmacother 2021;133:110943.
50. Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res 2018; 6:10-19.
51. Zhai R, Tang F, Gong J, Zhang J, Lei B, Li B, et al. The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis. Onco Targets Ther 2016; 9:6987-6998.
52. Zhang K, Fang T, Shao Y, Wu Y. TGF-β-MTA1-SMAD7-SMAD3-SOX4-EZH2 signaling axis promotes viability, migration, invasion and EMT of hepatocellular carcinoma cells. Cancer Manag Res 2021; 13:7087-7099.
53. Guo B, Tan X, Chen H. EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma. PloS One 2020; 15:1-16.
54. Xu L, Lin J, Deng W, Luo W, Huang Y, Liu C-Q, et al. EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c. Oncogenesis 2020; 9:101-116.
کارگاه‌های آموزشی مرکز اطلاعات علمی

آموزش مهارت‌های کاربردی ISI در تدوین و چاپ مقالات
روش تحقیق کمی
آموزش نرم‌افزار برای پژوهشگران

Word